SCA
RGNX icon

Spearhead Capital Advisors’s Regenxbio RGNX Stock Holding History

Spearhead Capital Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,908
Closed -$389K – 223
2021
Q4 		$389K Buy
11,908
+670
+6% +$22.8K 0.05% 125
2021
Q3 		$471K Buy
11,238
+536
+5% +$19.3K 0.06% 105
2021
Q2 		$416K Buy
10,702
+1,694
+19% +$60.6K 0.06% 135
2021
Q1 		$307K Buy
+9,008
New +$384K 0.05% 165

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Spearhead Capital Advisors's RGNX Position: Q1 2022 in Review

Spearhead Capital Advisors sold out of Regenxbio (RGNX) in Q1 2022, closing a stake of 11,908 shares — an estimated $389K sold.

Spearhead Capital Advisors first reported a position in RGNX in Q1 2021 and held it in 4 quarters. The position peaked at $471K in Q3 2021. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2022.

  • Spearhead Capital Advisors reported no remaining Regenxbio position as of Q1 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 11,908 Regenxbio shares in Q1 2022, an estimated $389K.
  • Spearhead Capital Advisors first reported a position in Regenxbio in Q1 2021 and held it in 4 quarters.
  • Spearhead Capital Advisors's Regenxbio position peaked at $471K in Q3 2021.
  • 188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2022.

Based on Spearhead Capital Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.